IO Biotech Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for IO Biotech, Inc. (IOBT) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-95.49-86.08-71.46-67.88-12.04
Depreciation & Amortization0.850.760.540.000.00
Deferred Income Tax0.000.000.090.000.00
Stock Based Compensation6.538.067.041.790.06
Change in Working Capital2.185.864.19-0.780.15
Change in Accounts Payable0.78-0.130.083.41-0.48
Change in Other Working Capital1.405.994.1226.540.62
Other Operating Activities3.597.46-0.0426.541.87
Net Cash from Operating Activities-82.35-71.74-59.73-40.65-9.96
Investing Activities
Capital Expenditures-0.04-0.32-0.69-0.150.00
Net Cash from Investing Activities-0.04-0.32-0.69-0.150.00
Financing Activities
Common Stock Issued0.0075.060.00115.120.00
Other Financing Activities0.00-3.200.00-12.11-0.01
Net Cash from Financing Activities0.0071.860.00252.955.10
Summary
Effect of Forex Changes on Cash-0.770.80-8.52-3.760.00
Net Change in Cash-83.16-0.20-68.94212.15-4.44
Cash at Beginning of Period143.46142.86211.803.410.00
Cash at End of Period60.30143.46142.59211.800.00
Free Cash Flow-82.39-72.06-60.42-40.80-9.96